Original Article
Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women
N Engl J Med 2006; 354:2645-2654June 22, 2006
- Abstract
Background
To evaluate whether the use of male condoms reduces the risk of male-to-female transmission of human papillomavirus (HPV) infection, longitudinal studies explicitly designed to evaluate the temporal relationship between condom use and HPV infection are needed.
Methods
We followed 82 female university students who reported their first intercourse with a male partner either during the study period or within two weeks before enrollment. Cervical and vulvovaginal samples for HPV DNA testing and Papanicolaou testing were collected at gynecologic examinations every four months. Every two weeks, women used electronic diaries to record information about their daily sexual behavior. Cox proportional-hazards models were used to evaluate risk factors for HPV infection.
Results
The incidence of genital HPV infection was 37.8 per 100 patient-years at risk among women whose partners used condoms for all instances of intercourse during the eight months before testing, as compared with 89.3 per 100 patient-years at risk in women whose partners used condoms less than 5 percent of the time (adjusted hazard ratio, 0.3; 95 percent confidence interval, 0.1 to 0.6, adjusted for the number of new partners and the number of previous partners of the male partner). Similar associations were observed when the analysis was restricted to high-risk and low-risk types of HPV and HPV types 6, 11, 16, and 18. In women reporting 100 percent condom use by their partners, no cervical squamous intraepithelial lesions were detected in 32 patient-years at risk, whereas 14 incident lesions were detected during 97 patient-years at risk among women whose partners did not use condoms or used them less consistently.
Conclusions
Among newly sexually active women, consistent condom use by their partners appears to reduce the risk of cervical and vulvovaginal HPV infection.
Media in This Article
Figure 1
Enrollment and Status of Subjects.Figure 2
Time at Risk for HPV, According to Cox Proportional-Hazards Models.Article Activity
- Article
Genital human papillomavirus (HPV) infections are common in sexually active young women,1-4 and certain types of HPV are causally related to anogenital cancers5 and warts.6 Although evidence demonstrates that the use of condoms by men substantially reduces the risk of genital transmission of human immunodeficiency virus in women,7 data on the effectiveness of condoms in reducing the incidence of other sexually transmitted infections are more limited.8,9 In particular, several studies have found that condom use by men does not reduce the risk of HPV infection in women,1,4,10-13 and recent congressional hearings have addressed changing Food and Drug Administration regulations on condom labeling.14 Most data on condom use and HPV infection, however, are from cross-sectional studies,10-13,15 and the prospective studies reported to date were not explicitly designed to evaluate condom use.1,4 Our longitudinal study was designed to evaluate more accurately the temporal relationship between condom use and HPV infection.
Methods
Study Design
We restricted eligibility to female University of Washington undergraduates who were 18 to 22 years old and who had never had vaginal intercourse or had first had intercourse with one male partner within the previous three months. In addition, the women had to have a cervix, could not be pregnant, had to be in good general health, and had to be able to provide written informed consent. Since the goal of the study was to enroll a population of healthy women (rather than women presenting to the student health clinic with gynecological problems), between December 2000 and June 2005, we mailed invitational letters to 24,201 women who met the age criterion and who released their names to the registrar. Given the restrictive eligibility criteria, we assumed that the number of participants would be low in relation to the number of letters mailed. We also provided informational flyers to contraceptive counselors at the student health clinic. Of the 243 eligible women who responded, 210 agreed to participate (86.4 percent) (Figure 1Figure 1
Enrollment and Status of Subjects.). The protocol was approved by the institutional review board at the University of Washington.Participants completed a Web-based diary regarding their sexual behavior every two weeks and underwent gynecologic examination every four months. Diary features have been described previously.16 The diary contained daily information regarding the number of instances of vaginal intercourse, the frequency of use of condoms by male partners, and the number of new partners. The first entry covered the two weeks before enrollment, and subsequent entries covered each successive two-week period. Missed diary entries could be made up within four months.
Clinical Measurements
At each visit to the clinic, a nurse practitioner conducted a face-to-face interview. Women were then instructed to obtain a vaginal sample with a Dacron-tipped swab and place it in a tube containing a specimen-transport medium for HPV testing. The nurse practitioner then performed a standardized pelvic examination. Separate cervical and vulvovaginal samples were obtained with Dacron-tipped swabs and placed in tubes containing transport medium for HPV testing. For Papanicolaou (Pap) testing, a cytobrush was used to collect cellular material from the endocervix and a plastic spatula was used to collect cells from the squamocolumnar junction and ectocervix.
Specimens were tested for HPV DNA with the use of a polymerase-chain-reaction (PCR) assay.17 DNA was isolated with the use of the QIAamp DNA blood kit (Qiagen) according to the manufacturer's protocol. Of each sample, 1/250 was amplified and 10 μl of PCR products was dotted onto nylon filters and probed with a biotin-labeled generic probe. Specimens that were found to be positive with the use of a generic probe were then typed with the use of a reverse line-blot assay (Roche Molecular Systems). Positive samples were first amplified simultaneously for HPV and β globin with the use of biotinylated PGMY09/PGMY11 and PC04/GH20 primers. A total of 70 μl of denatured PCR product was added to each well of an Amplicor typing tray containing 3 ml of preheated hybridization solution and a strip containing β globin and HPV oligonucleotide probes for 37 HPV types. Samples negative for β globin were considered insufficient for testing. Unless otherwise noted, PCR results for self-collected swabs and clinician-collected cervical and vulvovaginal swabs were combined to analyze acquisition and risk factors for genital infection. A cytotechnologist examined all Pap smears, and a pathologist reviewed all abnormal smears. Findings were classified according to the Bethesda system18 as normal, atypical, low-grade squamous intraepithelial lesion, or high-grade squamous intraepithelial lesion.
Statistical Analysis
Analyses were restricted to women with at least one follow-up visit after they first had intercourse. Excluded from the study were 65 women who reported having had no vaginal intercourse, 3 women who did not record any information in their diaries regarding sexual behavior, and 60 women who reported having first had intercourse more than two weeks before enrollment (Figure 1).
Incident HPV infection was defined as the first positive result for a specific type. The cumulative probability of HPV infection was estimated with the use of Kaplan–Meier methods. The time at risk was calculated from the date of first intercourse to the first detection of HPV. Kaplan–Meier methods were also used to estimate the cumulative probability of having cervical squamous intraepithelial lesions from the date of first intercourse.
Marginal Cox proportional-hazards models19 were used to determine risk factors for HPV infection. Data from diaries were summarized into risk-factor variables during the eight months before HPV testing, since most infections associated with a first partner (before the report of a second partner) occurred within eight months after a woman first had intercourse. Data recorded less than 20 days before a given visit were excluded, because 20 days was the shortest observed interval between the time a woman first had intercourse and the detection of an incident HPV infection in this study (Figure 2Figure 2
Time at Risk for HPV, According to Cox Proportional-Hazards Models.). The time to an event was measured from the time a woman first had intercourse to the report of infection with each type of HPV or the last clinic visit, with each woman contributing at-risk time for each of 37 HPV types. Analyses were stratified according to the type of HPV, assuming common relative hazards across HPV types while allowing the baseline hazards to vary. Robust variance estimates were used to account for correlation within subjects. Analyses were restricted to intervals in which intercourse was reported.Potential risk factors included the total number of instances of vaginal intercourse (continuous variable), the number of new partners (0, 1, or >1), the frequency of condom use by partners (<5 percent, 5 to 49 percent, 50 to 99 percent, or 100 percent), the partner's circumcision status (circumcised, uncircumcised, or unknown), and the partner's number of previous partners (0, ≥1, or unknown). The frequency of condom use was calculated by dividing the number of condoms used for vaginal intercourse by the number of instances of vaginal intercourse during the eight-month study period. If multiple new partners were reported during an eight-month period, the circumcision status and previous number of partners were summarized (Table 1Table 1
Incidence of Type-Specific HPV Infections and Cervical Squamous Intraepithelial Lesions Detected in 82 Women from the Date of First Intercourse, According to Selected Risk Factors.). The percentage of days that lacked diary entries was calculated to assess potential confounding created by missing data. The effect of the frequency of condom use was evaluated by multivariate analysis with the inclusion of other variables that were found to be significant (P<0.10) in univariate analyses. Similar analyses were performed to evaluate risk factors for high-risk types of HPV (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 73, and 82),20,21 low-risk types (6, 11, 40, 42, 54, 55, 57, 61, 62, 64, 69, 70, 71, 72, 81, 83, 84, and CP6108),20,21 and types 6, 11, 16, and 18 (which are included in quadrivalent vaccine trials22). To evaluate whether the effect of condom use on the risk of HPV infection differed according to the location in the genital tract, similar analyses were performed to examine risk factors for incident cervical and vulvovaginal infections.In subanalyses, subjects whose partners used condoms 100 percent of the time were divided into two categories on the basis of their responses to the question “Did your partner's penis ever touch the opening of your vagina without a condom?” If subjects always answered “no” for every act of vaginal intercourse during the eight-month period, they were coded as having had “no genital contact without a condom.” Analyses were performed as described above, with five categories of the frequency of condom use (100 percent without any genital contact without a condom, 100 percent with some or an unknown frequency of genital contact without a condom, and three groups below 100 percent, as described above).
Similarly, Cox proportional-hazards models were used to determine risk factors for the detection of incident cervical squamous intraepithelial lesions during the eight months before a given Pap test (on the basis of a previous observation that the majority of lesions occur soon after incident infection23). A 51-day lag before each visit was incorporated because 51 days was the shortest observed interval between the time a woman first had intercourse and the date of detection of an incident lesion in this study. Data for such subjects were censored after the first detection of an incident lesion.
Results
The mean (±SD) age of the 82 subjects at enrollment was 19.3±0.7 years. The subjects completed 709 visits. The mean follow-up time was 33.9±11.8 months, the mean number of visits per woman was 8.6±2.9, and the median time between visits was 4.1 months. Diary data were 90.7 percent complete, and condom data were recorded on 99.3 percent of days that intercourse was reported.
The 12-month cumulative incidence of a first HPV infection after first intercourse was 37.2 percent (95 percent confidence interval, 27.2 to 49.4 percent). A total of 126 incident type-specific infections were identified in 40 women after they first had intercourse (Table 2Table 2
Type-Specific Incidence of Genital HPV Infections Detected in 82 Women from the Date of First Intercourse.). Incident infections were identified in three women before they reported having intercourse for the first time, including one positive for HPV type 51, one for HPV type 6, and one for HPV types 40, 61, and 66. The 24-month cumulative incidence of cervical squamous intraepithelial lesions was 15.0 percent (95 percent confidence interval, 8.3 to 26.2 percent). Incident lesions were identified in 15 sexually active women, including 1 high-grade lesion and 14 low-grade lesions.The report of new partners in the previous eight months was associated with an increased risk of HPV infection. More frequent condom use by partners and a report of partners with no previous partners were both associated with a decreased risk (Table 3Table 3
Hazard Ratios for the Association between Behavioral Risk Factors and Incident HPV Infections and Incident Cervical Squamous Intraepithelial Lesions.). Not significant were the number of instances of vaginal intercourse (hazard ratio for each additional instance, 1.0; 95 percent confidence interval, 0.99 to 1.01), having a partner who was circumcised (hazard ratio for the comparison with having an uncircumcised partner, 0.7; 95 percent confidence interval, 0.3 to 1.5), and the percentage of missing diary days. In the multivariate model, two categories associated with a partner's number of previous partners (“1 or more” and “unknown”) were collapsed into one category because incident infections were identified among women whose partners were estimated to have had one or more or an unknown number of previous partners but not among women whose partners reportedly had had no previous partners.Women whose partners used condoms 100 percent of the time during the previous eight months were significantly less likely to acquire HPV than were those whose partners used condoms less than 5 percent of the time (Table 3). A linear categorical dose–response effect was observed, since the risk of incident HPV infection decreased with the increasing percentage of time a condom was used for intercourse (P=0.005 by the test for trend). Similar trends were observed through an analysis of risk factors for high-risk types of HPV, low-risk types of HPV, and HPV types 6, 11, 16, and 18 (Table 4Table 4
Hazard Ratios for the Association between the Frequency of Condom Use by Partners and Incident HPV Infections, According to the Type of HPV.) and for incident cervical and vulvovaginal HPV infection. Among the subgroup of women reporting 100 percent condom use by their partners during the previous eight months, the association between condom use and HPV infection was similar, regardless of whether any unprotected genital skin-to-skin contact was reported.Although incident cervical squamous intraepithelial lesions were positively associated with reports of new partners, associations with the prespecified categories of condom use were not significant (Table 3). However, as shown in Table 1, no lesions were detected during 32 patient-years at risk among women reporting 100 percent condom use by their partners during the previous eight months, whereas 14 lesions were detected during 97 patient-years at risk among women reporting less consistent use or nonuse of condoms by their partners. The number of previous partners reported for the partner, the number of instances of vaginal intercourse, circumcision status, and the percentage of missing diary days were not significant.
Discussion
Previous studies have suggested that the use of condoms by men offers women little if any protection against genital HPV infection.1,4,10-13 The results of our study, which was specifically designed to collect detailed and current data on condom use, suggest that male condoms effectively reduce the risk of male-to-female genital HPV transmission. Women whose partners used condoms for all instances of vaginal intercourse during the previous eight months were 70 percent less likely to acquire a new infection than were women whose partners used condoms less than 5 percent of the time, after adjustment for the number of new partners and the estimated number of previous partners of the male partner. Even women whose partners used condoms more than half the time had a 50 percent risk reduction, as compared with those whose partners used condoms less than 5 percent of the time.
Design features unique to our study may explain why we detected a significant inverse association between the frequency of condom use and HPV infection, whereas previous studies did not. First, the longitudinal design allowed us to evaluate the temporal relationship between condom use and HPV infection. Cross-sectional studies measuring prevalent infection may be misleading, since a temporal sequence cannot be established and most HPV infections are detected transiently.2,4 Second, previous studies (including our previous longitudinal study of a different cohort of women1) tended to rely on broad measures of condom use such as “always” or “always or sometimes” as compared with “never” or “never or sometimes,” recalled months or years later. By collecting information every two weeks, we minimized the potential for measurement error and more precisely measured the frequency of condom use.
Furthermore, evidence suggests that computer-assisted questionnaires yield more truthful reporting of sensitive behavior than do face-to-face interviews.24,25 With electronic diaries, we aimed to reduce reporting biases related to social desirability (such as the overreporting of condom use) that could dilute any true analysis of the effect of condoms. By asking women to report information about their partners, we also minimized potential confounding by sexual behavior. For example, women may be more likely to use condoms with partners they perceive as “risky.”26 Indeed, women who reported that their partners had had one or more or an unknown number of previous partners were more likely to have their partners use condoms than were women who reported that their partners were virgins. Although ideally one would measure the HPV status of all male partners, the fact that no incident infections were detected among women reporting previously virginal partners suggests that this variable is a useful indicator of a partner's infection status in a university setting. Finally, given the ubiquity of HPV infection among sexually active young women, we restricted our analyses of risk factors to women who first had intercourse within two weeks before enrollment or during the study. The enrollment of women with minimal previous exposure helped ensure that the cohort was susceptible to new infections and that infections detected during follow-up were truly incident.
We also observed an inverse association between the frequency of condom use and the incidence of cervical squamous intraepithelial lesions, although no significant associations with the prespecified categories of condom use were observed. However, no incident lesions were detected among women reporting 100 percent condom use by their partners during the previous eight months, whereas 14 incident lesions (14.5 per 100 patient-years at risk) were detected among women whose partners used condoms less consistently or never used condoms (although this analysis was conducted a posteriori). Although this trend is consistent with previous data indicating that condom use by their male partners protects some women against high-grade cervical neoplasia27,28 and invasive cervical cancer,29,30 larger data sets would be needed to determine the significance of the observed trend associated with 100 percent condom use.
Even though our primary aim was to evaluate the frequency of condom use in relation to HPV infection, we were also interested in evaluating whether unprotected nonpenetrative genital contact would diminish the effectiveness of condoms. The question “Did your partner's penis ever touch the opening of your vagina without a condom?” was intended to capture the incidence of unprotected genital contact while keeping the time required for making diary entries to a minimum. Women who reported 100 percent condom use by their partners and no genital skin-to-skin contact and those reporting some or an unknown amount of such contact had a similar incidence of HPV infection. Therefore, either our question was not a sensitive or specific marker of unprotected genital contact or brief episodes of skin-to-skin contact are not particularly efficient for male-to-female HPV transmission. Questions that specifically address condom breakage or slippage31 (problems particularly common among inexperienced users32) may be important, though such indicators may be more relevant for infections transmitted primarily through secretions.
Some limitations of the study should be noted. First, it is difficult to determine the optimal time frame for an assessment of risk factors for acquiring HPV infection. In retrospect, the 20-day lag period was relevant not only because it was the shortest observed interval between first intercourse and the detection of HPV infection in this study but also because it is within the range of time estimated for epithelial cells to mature and differentiate,33 cellular events that are required for HPV replication.34 Although an eight-month period was used because the majority of first infections associated with a first partner occurred within this time frame, not all partners are infectious, a partner's infectivity may change, and infection could have occurred at any time within the eight-month period. If infection occurred early, for example, condom use for intercourse reported later in the interval would be unrelated to HPV status, and the true effect of condoms might be diluted.
Furthermore, incomplete reporting could have created a misclassification of the frequency of condom use, although such an effect probably would have been minimal, given the small percentage of days with missing data regarding sexual behavior. Incomplete follow-up and delayed or missed clinical visits were other potential sources of bias. For example, outcomes of short duration could be missed with less frequent follow-up, potentially leading to underestimates of the cumulative incidences of infection and lesions. However, when we compared women with average visit intervals of less than four months with those with intervals of four months or more, we observed similar rates of HPV infection (P=0.43). In a comparison of women who were eventually lost to follow-up with those who were not, similar rates of HPV infection were observed during the study (P=0.56).
Finally, although the newly sexually active women in our cohort reported a yearly median number of instances of intercourse (48) and a yearly median number of new partners (1) that were similar to those reported in a large national survey of a random sample of women of a similar age,35 our results may not be generalizable to populations of older women or women of lower socioeconomic status.
Our study demonstrates an inverse, temporal association between the frequency of condom use by male partners and the risk of HPV infection in women. The association was strong and increased with the increasing frequency of condom use, suggesting a causal, protective effect. Given that HPV is transmissible through nonpenetrative sexual contact with both male1 and female36 partners and that imperfect condom use does occur, it is not surprising that some infections were still detected among women reporting consistent use. It is encouraging, however, that the women in this cohort, who were new to sexual intercourse and condom use, were able to reduce their risk of HPV infection through the consistent use of condoms by male partners. Furthermore, our results suggest that consistent condom use offers similar protection against both high-risk and low-risk types of HPV. Even after the quadrivalent vaccine for HPV types 6, 11, 16, and 18 becomes available, consistent condom use by their partners may protect women against infection with other high-risk types of HPV that put them at risk for cervical cancer.
Presented in part at the 16th Biennial Meeting of the International Society of Sexually Transmitted Research, Amsterdam, the Netherlands, July 10–13, 2005.
Supported in part by grants (RO1-A138383 and T32-AI007140-24) from the National Institute of Allergy and Infectious Diseases.
Dr. Winer reports having received consulting fees from Merck; Dr. Holmes, fees for serving on advisory boards for Merck and GlaxoSmithKline; and Dr. Koutsky, research funding from Merck. No other potential conflict of interest relevant to this article was reported.
We are indebted to Thomas Koepsell, M.D., M.P.H., for his critical review of the manuscript, and to Marsha Weese for her assistance with editing.
Source Information
From the Departments of Epidemiology (R.L.W., S.O., L.A.K.), Biostatistics (J.P.H.), and Pathology (Q.F., N.B.K.), and the Center for AIDS and STD (K.K.H.), University of Washington, Seattle.
Address reprint requests to Dr. Winer at the University of Washington HPV Research Group, Lake Union Place, Suite 300, 1914 N. 34th St., Seattle, WA 98103, or at rlw@u.washington.edu.
- References
References
1
Winer RL ,Lee SK ,Hughes JP ,Adam DE ,Kiviat NB ,Koutsky LA . Genital human papillomavirus infection: rates and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-226[Erratum, Am J Epidemiol 2003;157:858.]
CrossRef | Web of Science | Medline2
Woodman CB ,Collins S ,Winter H , et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-1836
CrossRef | Web of Science | Medline3
Moscicki AB ,Hills N ,Shiboski S , et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002
CrossRef | Web of Science | Medline4
Ho GYF ,Bierman R ,Beardsley L ,Chang CJ ,Burk RD . Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428
Full Text | Web of Science | Medline5
Bosch FX ,Manos MM ,Munoz N , et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802
CrossRef | Web of Science | Medline6
Greer CE ,Wheeler CM ,Ladner MB , et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33:2058-2063
Web of Science | Medline7
Weller S ,Davis K . Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002;1:CD003255-CD003255
Medline8
Holmes KK ,Levine R ,Weaver M . Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004;82:454-461
Web of Science | Medline9
Zenilman JM ,Weisman CS ,Rompalo AM , et al. Condom use to prevent incident STDs: the validity of self-reported condom use. Sex Transm Dis 1995;22:15-21
CrossRef | Web of Science | Medline10
Davidson M ,Schnitzer PG ,Bulkow LR , et al. The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaska Native women. J Infect Dis 1994;169:792-800
CrossRef | Web of Science | Medline11
Jamison JH ,Kaplan DW ,Hamman R ,Eagar R ,Beach R ,Douglas JM Jr . Spectrum of genital human papillomavirus infection in a female adolescent population. Sex Transm Dis 1995;22:236-243
CrossRef | Web of Science | Medline12
Young TK ,McNicol P ,Beauvais J . Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian Aboriginal and non-Aboriginal women. Sex Transm Dis 1997;24:293-298
CrossRef | Web of Science | Medline13
Kjaer SK ,Svare EI ,Worm AM ,Walboomers JM ,Meijer CJ ,van den Brule AJ . Human papillomavirus infection in Danish female sex workers: decreasing prevalence with age despite continuously high sexual activity. Sex Transm Dis 2000;27:4 38-45
Web of Science14
Christopher A . Hearing addresses condoms for HPV prevention. J Natl Cancer Inst 2004;96:985-985
Web of Science | Medline15
Kjaer SK ,van den Brule AJ ,Bock JE , et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997;6:799-805
Web of Science | Medline16
Baer A ,Saroiu S ,Koutsky LA . Obtaining sensitive data through the Web: an example of design and methods. Epidemiology 2002;13:640-645
CrossRef | Web of Science | Medline17
Weaver BA ,Feng Q ,Holmes KK , et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 2004;189:677-685
CrossRef | Web of Science | Medline18
Kurman RJ ,Henson DE ,Herbst AL ,Noller KL ,Schiffman MH . Interim guidelines for management of abnormal cervical cytology: the 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-1869
CrossRef | Web of Science | Medline19
Wei LJ ,Lin DY ,Weissfeld L . Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989;84:1065-1073
CrossRef | Web of Science20
de Villiers EM ,Fauquet C ,Broker TR ,Bernard HU ,zur Hausen H . Classification of papillomaviruses. Virology 2004;324:17-27
CrossRef | Web of Science | Medline21
Munoz N ,Bosch FX ,de Sanjose S , et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527
Full Text | Web of Science | Medline22
Koutsky LA ,Ault KA ,Wheeler CM , et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651
Full Text | Web of Science | Medline23
Winer RL ,Kiviat NB ,Hughes JP , et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-738
CrossRef | Web of Science | Medline24
Turner CF ,Ku L ,Rogers SM ,Lindberg LD ,Pleck JH ,Sonenstein FL . Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science 1998;280:867-873
CrossRef | Web of Science | Medline25
Locke SE ,Kowaloff HB ,Hoff RG , et al. Computer-based interview for screening blood donors for risk of HIV transmission. JAMA 1992;268:1301-1305
CrossRef | Web of Science | Medline26
Peterman TA ,Lin LS ,Newman DR , et al. Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Sex Transm Dis 2000;27:446-451
CrossRef | Web of Science | Medline27
Wang PD ,Lin RS . Risk factors for cervical intraepithelial neoplasia in Taiwan. Gynecol Oncol 1996;62:10-18
CrossRef | Web of Science | Medline28
Ho GY ,Kadish AS ,Burk RD , et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998;78:281-285
CrossRef | Web of Science | Medline29
Thomas DB ,Ray RM ,Pardthaisong T , et al. Prostitution, condom use, and invasive squamous cell cervical cancer in Thailand. Am J Epidemiol 1996;143:779-786
Web of Science | Medline30
Kjaer SK ,de Villiers EM ,Dahl C , et al. Case-control study of risk factors for cervical neoplasia in Denmark. I: Role of the “male factor” in women with one lifetime sexual partner. Int J Cancer 1991;48:39-44
CrossRef | Web of Science | Medline31
Paz-Bailey G ,Koumans EH ,Sternberg M , et al. The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents. Arch Pediatr Adolesc Med 2005;159:536-542
CrossRef | Web of Science | Medline32
Sparrow MJ ,Lavill K . Breakage and slippage of condoms in family planning clients. Contraception 1994;50:117-129
CrossRef | Web of Science | Medline33
Dover R, Wright NA. Biology and function of epidermis and appendages. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds. Dermatology in general medicine. Vol. I. New York: McGraw-Hill, 1993:165.
34
Meyers C ,Frattini MG ,Hudson JB ,Laimins LA . Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992;257:971-973
CrossRef | Web of Science | Medline35
Shafii T, Stovel K, Holmes KK. Is condom use at sexual debut associated with different sexual trajectories? A longitudinal study with biomarkers. Am J Public Health (in press).
36
Marrazzo JM ,Koutsky LA ,Stine KL , et al. Genital human papillomavirus infection in women who have sex with women. J Infect Dis 1998;178:1604-1609
CrossRef | Web of Science | Medline
- Citing Articles (132)
Citing Articles
1
Richard G. Wamai, Claudine Akono Ayissi, Geofrey O. Oduwo, Stacey Perlman, Edith Welty, Simon Manga, Javier Gordon Ogembo. (2012) Assessing the Effectiveness of a Community-Based Sensitization Strategy in Creating Awareness About HPV, Cervical Cancer and HPV Vaccine Among Parents in North West Cameroon. Journal of Community Health
CrossRef2
Marjorie Jenkins, Maurizio Chiriva-Internati, Leonardo Mirandola, Catherine Tonroy, Sean S. Tedjarati, Nicole Davis, Nicholas D'Cunha, Lukman Tijani, Fred Hardwick, Diane Nguyen, W. Martin Kast, Everardo Cobos. (2012) Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach. International Reviews of Immunology 31:1, 3-21
CrossRef3
J. M. Marrazzo, W. Cates. (2011) Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. Clinical Infectious Diseases 53:suppl 3, S64-S78
CrossRef4
E. F. Dunne, A. Friedman, S. D. Datta, L. E. Markowitz, K. A. Workowski. (2011) Updates on Human Papillomavirus and Genital Warts and Counseling Messages From the 2010 Sexually Transmitted Diseases Treatment Guidelines. Clinical Infectious Diseases 53:suppl 3, S143-S152
CrossRef5
A. Neumeyer-Gromen, N. Bodemer, S.M. Müller, G. Gigerenzer. (2011) Ermöglichen Medienberichte und Broschüren informierte Entscheidungen zur Gebärmutterhalskrebsprävention?. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 54:11, 1197-1210
CrossRef6
N. Larke, S. L. Thomas, I. dos Santos Silva, H. A. Weiss. (2011) Male Circumcision and Human Papillomavirus Infection in Men: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases 204:9, 1375-1390
CrossRef7
E. MAREK, T. DERGEZ, S. BOZSA, K. GOCZE, G. REBEK-NAGY, A. KRICSKOVICS, I. KISS, I. EMBER, P. GOCZE. (2011) Incomplete knowledge - unclarified roles in sex education: results of a national survey about human papillomavirus infections. European Journal of Cancer Care 20:6, 759-768
CrossRef8
C.M.R. Ouedraogo, F.W. Djigma, C. Bisseye, T. Sagna, M. Zeba, D. Ouermi, S.D. Karou, V. Pietra, F. Buelli, N.W. Ghilat-Avoid-Belem, K. Sanogo, J. Sempore, R. Moret, S. Pignatelli, J.-B. Nikiema, J. Simpore. (2011) Épidémiologie et caractérisation des génotypes de papillomavirus humain dans une population de femmes à Ouagadougou. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 40:7, 633-638
CrossRef9
L. Sabiani, A. Bremond, I. Mortier, M. Lecuyer, L. Boubli, X. Carcopino. (2011) Évaluation de la couverture vaccinale du vaccin anti-hpv : résultats d’une enquête auprès des lycéennes et étudiantes de la région PACA. Journal de Gynécologie Obstétrique et Biologie de la Reproduction
CrossRef10
Joseph E. Tota, Myriam Chevarie-Davis, Lyndsay A. Richardson, Maaike deVries, Eduardo L. Franco. (2011) Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Preventive Medicine 53, S12-S21
CrossRef11
Antonio Frega, Paolo Scirpa, Francesco Sopracordevole, Alberto Biamonti, Paola Bianchi, Luana De Sanctis, Laura Lorenzon, Arianna Pacchiarotti, Deborah French, Massimo Moscarini. (2011) Impact of human papillomavirus infection on the neovaginal and vulval tissues of women who underwent surgical treatment for Mayer-Rokitansky-Kuster-Hauser syndrome. Fertility and Sterility 96:4, 969-973
CrossRef12
C. González, M. Torres, J. Canals, E. Fernández, J. Belda, M. Ortiz, J. Del Amo. (2011) Higher incidence and persistence of high-risk human papillomavirus infection in female sex workers compared with women attending family planning. International Journal of Infectious Diseases 15:10, e688-e694
CrossRef13
Xavier Castellsagué, Mireia Díaz, Salvatore Vaccarella, Silvia de Sanjosé, Nubia Muñoz, Rolando Herrero, Silvia Franceschi, Chris J L M Meijer, F Xavier Bosch. (2011) Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. The Lancet Oncology 12:11, 1023-1031
CrossRef14
Henrike J. Vriend, Hein J. Boot, Marianne A. B. van der Sande. (2011) Type-Specific Human Papillomavirus Infections Among Young Heterosexual Male and Female STI Clinic Attendees. Sexually Transmitted Diseases1
CrossRef15
Yasmin L Jayasinghe, Elya E Moore, Sepehr N Tabrizi, Sonia R Grover, Suzanne M Garland. (2011) Human papillomavirus in adolescents: Lessons learned from decades of evaluation. Journal of Paediatrics and Child Healthno-no
CrossRef16
Jeffrey F. Peipert, Qiuhong Zhao, Laura Meints, Benjamin J. Peipert, Colleen A. Redding, Jenifer E. Allsworth. (2011) Adherence to dual-method contraceptive use. Contraception 84:3, 252-258
CrossRef17
S. Rückert, N. Ditsch, J. Gallwas, C. Dannecker. (2011) HPV-Infektion in der Schwangerschaft. Der Gynäkologe 44:8, 630-636
CrossRef18
Sherri N. Sheinfeld Gorin, Beth A. Glenn, Rebecca B. Perkins. (2011) The human papillomavirus (HPV) vaccine and cervical cancer: Uptake and next steps. Advances in Therapy 28:8, 615-639
CrossRef19
Z. R. Edelstein, J. J. Carter, R. Garg, R. L. Winer, Q. Feng, D. A. Galloway, L. A. Koutsky. (2011) Serum Antibody Response Following Genital 9 Human Papillomavirus Infection in Young Men. Journal of Infectious Diseases 204:2, 209-216
CrossRef20
Maribel Almonte, Isabel dos Santos Silva, Akua Asare, Clare Gilham, Alexandra Sargent, Andrew Bailey, Andrew Turner, Mina Desai, Henry C. Kitchener, Julian Peto. (2011) Sexual behavior and HPV infection in British women, by postal questionnaires and telephone interviews. Journal of Medical Virology 83:7, 1238-1246
CrossRef21
Soyeon Kim, Jean Marie Arduino, Christine C. Roberts, Mark Marsico, Kai-Li Liaw, Finn Egil Skjeldestad. (2011) Incidence and Predictors of Human Papillomavirus-6, -11, -16, and -18 Infection in Young Norwegian Women. Sexually Transmitted Diseases 38:7, 587-597
CrossRef22
Pere Godoy. (2011) La vigilancia y el control de las infecciones de transmisión sexual: todavía un problema pendiente. Gaceta Sanitaria 25:4, 263-266
CrossRef23
Maria Gottvall, Tanja Tydén, Margareta Larsson, Christina Stenhammar, Anna T. Höglund. (2011) Challenges and opportunities of a new HPV immunization program. Vaccine 29:28, 4576-4583
CrossRef24
J.-J. Baldauf, M. Fender, C. Youssef Azer Akladios, M. Velten. (2011) Le dépistage précoce du cancer du col est-il justifié ?. Gynécologie Obstétrique & Fertilité 39:6, 358-363
CrossRef25
Allison G. Litton, Renee A. Desmond, Janice Gilliland, Warner K. Huh, Frank A. Franklin. (2011) Factors Associated with Intention to Vaccinate a Daughter against HPV: A Statewide Survey in Alabama. Journal of Pediatric and Adolescent Gynecology 24:3, 166-171
CrossRef26
Robin Quesenberry Olsen, Laura B. Cieraszynski, Shannon M. Bishop. (2011) Update on diagnosis, treatment, and prevention of genital human papillomavirus manifestations. Osteopathic Family Physician 3:3, 106-111
CrossRef27
Jonathan P Shepherd, Geoff K Frampton, Petra Harris, Jonathan P Shepherd. 2011. Interventions for encouraging sexual behaviours intended to prevent cervical cancer. .
CrossRef28
Xavier Carcopino, Noel Bolger, Mireille Henry, Julien Mancini, Léon Boubli, Daniel Olive, Sinead Cleary, Walter Prendiville, Catherine Tamalet. (2011) Evaluation of type-specific HPV persistence and high-risk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytology. Journal of Medical Virology 83:4, 637-643
CrossRef29
G. Valasoulis, G. Koliopoulos, C. Founta, M. Kyrgiou, I. Tsoumpou, O. Valari, P. Martin-Hirsch, A. Daponte, P. Karakitsos, E. Paraskevaidis. (2011) Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia. Gynecologic Oncology 121:1, 43-48
CrossRef30
Anita L. Nelson. 2011. Male Condoms. , 114-122.
CrossRef31
Justin M Julius, Lois Ramondeta, Katherine A Tipton, Lincy S Lal, Karen Schneider, Judith A Smith. (2011) Clinical Perspectives on the Role of the Human Papillomavirus Vaccine in the Prevention of Cancer. Pharmacotherapy 31:3, 280-297
CrossRef32
Joseph Monsonego. (2011) Genital infection with HPV in men: research into practice. The Lancet 377:9769, 881-883
CrossRef33
Erik Malmqvist, Gert Helgesson, Johannes Lehtinen, Kari Natunen, Matti Lehtinen. (2011) The ethics of implementing human papillomavirus vaccination in developed countries. Medicine, Health Care and Philosophy 14:1, 19-27
CrossRef34
Aine E. Clements, Christina A. Raker, Amy S. Cooper, Lori A. Boardman. (2011) Prevalence and patient characteristics associated with CIN 3 in adolescents. American Journal of Obstetrics and Gynecology 204:2, 128.e1-128.e7
CrossRef35
Heidi Y.M. Wong, Alice Y. Loke, Norman H.L. Chan. (2011) Risk Factors for Cervical Abnormalities Among Hong Kong Chinese Women: A Large-Scale Community-Based Cervical Screening Program. Journal of Women's Health 20:1, 53-59
CrossRef36
Kari Natunen, Johannes Lehtinen, Proscovia Namujju, John Sellors, Matti Lehtinen. (2011) Aspects of Prophylactic Vaccination against Cervical Cancer and Other Human Papillomavirus-Related Cancers in Developing Countries. Infectious Diseases in Obstetrics & Gynecology 2011, 1-10
CrossRef37
Brian J. Morris, Ronald H. Gray, Xavier Castellsague, F. Xavier Bosch, Daniel T. Halperin, Jake H. Waskett, Catherine A. Hankins. (2011) The Strong Protective Effect of Circumcision against Cancer of the Penis. Advances in Urology 2011, 1-21
CrossRef38
David Serfaty. 2011. Contraception masculine. , 266-283.
CrossRef39
David Serfaty. 2011. Infections sexuellement transmissibles. , 306-337.
CrossRef40
Nienke J Veldhuijzen, Peter JF Snijders, Peter Reiss, Chris JLM Meijer, Janneke HHM van de Wijgert. (2010) Factors affecting transmission of mucosal human papillomavirus. The Lancet Infectious Diseases 10:12, 862-874
CrossRef41
Michelle Forcier, Najah Musacchio. (2010) An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatologic Therapy 23:5, 458-476
CrossRef42
Michael Waugh. (2010) The role of condom use in sexually transmitted disease prevention: Facts and controversies. Clinics in Dermatology 28:5, 549-552
CrossRef43
S. Tafuri, D. Martinelli, M.M. Vece, M. Quarto, C. Germinario, R. Prato. (2010) Communication skills in HPV prevention: an audit among Italian healthcare workers. Vaccine 28:34, 5609-5613
CrossRef44
H. L. Gamble, J. L. Klosky, G. R. Parra, M. E. Randolph. (2010) Factors Influencing Familial Decision-Making Regarding Human Papillomavirus Vaccination. Journal of Pediatric Psychology 35:7, 704-715
CrossRef45
Suks Minhas, Andreas Manseck, Stephen Watya, Paul K. Hegarty. (2010) Penile Cancer—Prevention and Premalignant Conditions. Urology 76:2, S24-S35
CrossRef46
Mark Schiffman, Nicolas Wentzensen. (2010) From Human Papillomavirus to Cervical Cancer. Obstetrics & Gynecology 116:1, 177-185
CrossRef47
Margaret Stanley. (2010) Pathology and epidemiology of HPV infection in females. Gynecologic Oncology 117:2, S5-S10
CrossRef48
Alok C Bharti, Shirish Shukla, Sutapa Mahata, Suresh Hedau, Bhudev C Das. (2010) Human papillomavirus and control of cervical cancer in India. Expert Review of Obstetrics & Gynecology 5:3, 329-346
CrossRef49
F. Shiely, M. Horgan, K. Hayes. (2010) Increased sexually transmitted infection incidence in a low risk population: Identifying the risk factors. The European Journal of Public Health 20:2, 207-212
CrossRef50
Joel M. Palefsky. (2010) Human Papillomavirus-Related Disease in Men: Not Just a Women's Issue. Journal of Adolescent Health 46:4, S12-S19
CrossRef51
André Berchtold, Pierre-André Michaud, Denise Nardelli-Haefliger, Joan-Carles Surís. (2010) Vaccination against human papillomavirus in Switzerland: simulation of the impact on infection rates. International Journal of Public Health 55:1, 25-34
CrossRef52
Sue L. Moreni, Caroline M. Mitchell, Rochelle L. Garcia, Linda O. Eckert. (2010) Loop Electrosurgical Excisional Procedure (LEEP) Done for Discrepancy: Does the Time from HGSIL Affect Pathologic Grade of CIN in LEEP Specimen?. Obstetrics and Gynecology International 2010, 1-6
CrossRef53
Angel Chao, Chee-Jen Chang, Chyong-Huey Lai, Fang-Yu Chao, Yi-Hsien Hsu, Hung-Hsueh Chou, Huei-Jean Huang, Shih-Ming Jung, Cheng-Tao Lin, Hui-Hsin Cheng, Chu-Chun Huang, Jung-Erh Yang, Ting-Chang Chang. (2010) Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology
A population-based cohort study from Taiwan. International Journal of Cancer 126:1, 191-198
CrossRef54
David G. Regan, David J. Philp, Edward K. Waters. (2010) Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective. Sexual Health 7:3, 368
CrossRef55
Ann N. Burchell, Pierre-Paul Tellier, James Hanley, François Coutlée, Eduardo L. Franco. (2010) Influence of Partnerʼs Infection Status on Prevalent Human Papillomavirus Among Persons With a New Sex Partner. Sexually Transmitted Diseases 37:1, 34-40
CrossRef56
Anne M. Rompalo, Khalil G. Ghanem. 2010. Sexually Transmitted Infections in Men and Women. , 516-530.
CrossRef57
Karen Feisullin, Carolyn Westhoff. 2010. Contraception. , 357-365.
CrossRef58
Michael A. A. van Trotsenburg. (2009) Gynecological Aspects of Transgender Healthcare. International Journal of Transgenderism 11:4, 238-246
CrossRef59
Elsebeth Lynge, Ahti Antilla, Marc Arbyn, Nereo Segnan, Guglielmo Ronco. (2009) What’s next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. European Journal of Cancer 45:15, 2714-2721
CrossRef60
Ann Nielsen, Thomas Iftner, Christian Munk, Susanne K. Kjaer. (2009) Acquisition of High-Risk Human Papillomavirus Infection in a Population-Based Cohort of Danish Women. Sexually Transmitted Diseases 36:10, 609-615
CrossRef61
Lidia Rosi Medeiros, Daniela Dornelles Rosa, Maria Inês da Rosa, Mary Clarisse Bozzetti, Roselaine Ruviaro Zanini. (2009) Efficacy of Human Papillomavirus Vaccines. International Journal of Gynecological Cancer 19:7, 1166-1176
CrossRef62
Roman Prymula, Ioana Anca, Francis André, Mustafa Bakir, Hanna Czajka, Irja Lutsar, Zsófia Mészner, Nuran Salman, Pavol Šimurka, Vytautas Usonis. (2009) Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. European Journal of Pediatrics 168:9, 1031-1035
CrossRef63
Xavier Vallès, Gladys Beatriz Murga, Gabriela Hernández, Meritxell Sabidó, Alejandro Chuy, Belén Lloveras, Francesc Alameda, Sílvia de San José, Francesc Xavier Bosch, Isabel Pedroza, Xavier Castellsagué, Jordi Casabona. (2009) High prevalence of human papillomavirus infection in the female population of Guatemala. International Journal of Cancer 125:5, 1161-1167
CrossRef64
A. Senéjoux. (2009) Condylomes anaux. Côlon & Rectum 3:3, 146-150
CrossRef65
Kahn, Jessica A., . (2009) HPV Vaccination for the Prevention of Cervical Intraepithelial Neoplasia. New England Journal of Medicine 361:3, 271-278
Full Text66
Tiffany G. Harris, Leslie Miller, Shalini L. Kulasingam, Qinghua Feng, Nancy B. Kiviat, Stephen M. Schwartz, Laura A. Koutsky. (2009) Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. American Journal of Obstetrics and Gynecology 200:5, 489.e1-489.e8
CrossRef67
Marian Pitts, Anthony Smith, Samantha Croy, Anthony Lyons, Richard Ryall, Suzanne Garland, Mee Lian Wong, Tay Eng Hseon. (2009) Singaporean men's knowledge of cervical cancer and human papillomavirus (HPV) and their attitudes towards HPV vaccination. Vaccine 27:22, 2989-2993
CrossRef68
Rachel L. Winer, Tiffany G. Harris, Long Fu Xi, Kathrin U. Jansen, James P. Hughes, Qinghua Feng, Carolee Welebob, Jesse Ho, Shu-Kuang Lee, Joseph J. Carter, Denise A. Galloway, Nancy B. Kiviat, Laura A. Koutsky. (2009) Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. Journal of Medical Virology 81:4, 713-721
CrossRef69
M. C. G. Bleeker, D. A. M. Heideman, P. J. F. Snijders, S. Horenblas, J. Dillner, C. J. L. M. Meijer. (2009) Penile cancer: epidemiology, pathogenesis and prevention. World Journal of Urology 27:2, 141-150
CrossRef70
Ali Rowhani-Rahbar, James P. Hughes, Laura A. Koutsky. (2009) Difficulties in Estimating the Male-to-Female Sexual Transmissibility of Human Papillomavirus Infection. Sexually Transmitted Diseases 36:4, 261-263
CrossRef71
Rebecca S. French, Frances M. Cowan. (2009) Contraception for adolescents. Best Practice & Research Clinical Obstetrics & Gynaecology 23:2, 233-247
CrossRef72
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Goldstein, Mark A., Goodman, Annekathryn, del Carmen, Marcela G., Wilbur, David C., . (2009) Case 10-2009. New England Journal of Medicine 360:13, 1337-1344
Full Text73
Karen Hoover, Allison Friedman, Daniel Montaño, Danuta Kasprzyk, April Greek, Matthew Hogben. (2009) What About the Partners of Women With Abnormal Pap or Positive HPV Tests?. Sexually Transmitted Diseases 36:3, 141-146
CrossRef74
Beatriz Grinsztejn, Valdilea Gonçalves Veloso, José Eduardo Levi, Luciane Velasque, Paula Mendes Luz, Ruth Khalili Friedman, Angela Cristina Andrade, Ronaldo Ismerio Moreira, Fabio Russomano, José Henrique Pilotto, Francisco Inacio Bastos, Joel Palefsky. (2009) Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women. International Journal of Infectious Diseases 13:1, 72-80
CrossRef75
Richard Crosby, Kristin Rager, Amy Hanson, Julie Ribes. (2008) Does Knowing about an HPV Infection Influence Behavior Change? A Feasibility Study of Females Attending a Teen Clinic. Journal of Pediatric and Adolescent Gynecology 21:6, 373-376
CrossRef76
Anna-Barbara Moscicki. (2008) Management of Adolescents Who Have Abnormal Cytology and Histology. Obstetrics and Gynecology Clinics of North America 35:4, 633-643
CrossRef77
Kathryn Doherty, Kathryn Graff Low. (2008) The Effects of a Web-Based Intervention on College Students' Knowledge of Human Papillomavirus and Attitudes toward Vaccination. International Journal of Sexual Health 20:4, 223-232
CrossRef78
Lucia Six, Sepp Leodolter, Heather L. Sings, Eliav Barr, Richard Haupt, Elmar A. Joura. (2008) Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women – baseline data of a phase III vaccine trial. Wiener klinische Wochenschrift 120:21-22, 666-671
CrossRef79
George F. Sawaya, Mike Zvavahera Chirenje, Mildred Tsitsi Magure, Jennifer L. Tuveson, Yifei Ma, Stephen C. Shiboski, Maria M. Da Costa, Joel M. Palefsky, Anna-Barbara Moscicki, Rudo Makunike Mutasa, Tsungai Chipato, Karen K. Smith-McCune. (2008) Effect of Diaphragm and Lubricant Gel Provision on Human Papillomavirus Infection Among Women Provided With Condoms. Obstetrics & Gynecology 112:5, 990-997
CrossRef80
Maaike A. van der Aa, Sabine Siesling, Marieke W. Louwman, Otto Visser, Eero Pukkala, Jan Willem W. Coebergh. (2008) Geographical relationships between sociodemographic factors and incidence of cervical cancer in the Netherlands 1989–2003. European Journal of Cancer Prevention 17:5, 453-459
CrossRef81
Felix Aigner, Friedrich Conrad, Andreas Widschwendter, Robert Zangerle, Bettina Zelger, Alfred Haidenberger, Sebastian Roka, Kurt Heim, Reinhard Höpfl, Martin Klimpfinger, Yves Marcus Rigler, Hugo Bonatti, Johann Pfeifer, Andrea Maier, Reinhard Kirnbauer, Andreas Salat. (2008) Anale HPV-Infektionen. Wiener klinische Wochenschrift 120:19-20, 631-641
CrossRef82
Lea E. Widdice, Anna-Barbara Moscicki. (2008) Updated Guidelines for Papanicolaou Tests, Colposcopy, and Human Papillomavirus Testing in Adolescents. Journal of Adolescent Health 43:4, S41-S51
CrossRef83
Douglas R. Lowy, Diane Solomon, Allan Hildesheim, John T. Schiller, Mark Schiffman. (2008) Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 113:S7, 1980-1993
CrossRef84
Bruce G. Trigg, Peter R. Kerndt, Getahun Aynalem. (2008) Sexually Transmitted Infections and Pelvic Inflammatory Disease in Women. Medical Clinics of North America 92:5, 1083-1113
CrossRef85
Alison Jeanne Lin, John S. Santelli. (2008) The accuracy of condom information in three selected abstinence-only education curricula. Sexuality Research and Social Policy 5:3, 56-69
CrossRef86
Jean Hamlin, Selvi Senthilnathan, Henry H Bernstein. (2008) Update on universal childhood immunizations. Current Opinion in Pediatrics 20:4, 483-489
CrossRef87
P. Hillemanns. (2008) Prävention von Zervix- und Vulvakarzinomen. Der Gynäkologe 41:7, 500-507
CrossRef88
Edward John Mayeaux, Charles Dunton. (2008) Modern Management of External Genital Warts. Journal of Lower Genital Tract Disease 12:3, 185-192
CrossRef89
RICHARD GUIDO. (2008) Human Papillomavirus and Cervical Disease in Adolescents. Clinical Obstetrics and Gynecology 51:2, 290-305
CrossRef90
Maria Lina Diaz. (2008) Human Papilloma Virus – Prevention and Treatment. Obstetrics and Gynecology Clinics of North America 35:2, 199-217
CrossRef91
Christine M. Huang. (2008) Human Papillomavirus and Vaccination. Mayo Clinic Proceedings 83:6, 701-707
CrossRef92
C. M. Huang. (2008) Human Papillomavirus and Vaccination. Mayo Clinic Proceedings 83:6, 701-707
CrossRef93
Shelley Miksis. (2008) A Review of the Evidence Comparing the Human Papillomavirus Vaccine Versus Condoms in the Prevention of Human Papillomavirus Infections. Journal of Obstetric, Gynecologic, & Neonatal Nursing 37:3, 329-337
CrossRef94
Pamela K. Kohler, Lisa E. Manhart, William E. Lafferty. (2008) Abstinence-Only and Comprehensive Sex Education and the Initiation of Sexual Activity and Teen Pregnancy. Journal of Adolescent Health 42:4, 344-351
CrossRef95
Peter V. Chin‐Hong. (2008) Cutting Human Papillomavirus Infection in Men. The Journal of Infectious Diseases 197:6, 781-783
CrossRef96
Philip E. Castle. (2008) Human Papillomavirus (HPV) Genotype 84 Infection of the Male Genitalia: Further Evidence for HPV Tissue Tropism?. The Journal of Infectious Diseases 197:5, 776-778
CrossRef97
Rachel L. Winer, Qinghua Feng, James P. Hughes, Sandra O’Reilly, Nancy B. Kiviat, Laura A. Koutsky. (2008) Risk of Female Human Papillomavirus Acquisition Associated with First Male Sex Partner. The Journal of Infectious Diseases 197:2, 279-282
CrossRef98
J.A. Stockman. (2008) Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women. Yearbook of Pediatrics 2008, 9-11
CrossRef99
Richard Crosby, Lee Warner. (2008) Pending research issues in male condom use promotion. Sexual Health 5:4, 317
CrossRef100
Adrian Mindel, Shailendra Sawleshwarkar. (2008) Condoms for sexually transmissible infection prevention: politics versus science. Sexual Health 5:1, 1
CrossRef101
Wendy R. Holmes, Lisa Maher, Susan L. Rosenthal. (2008) Attitudes of men in an Australian male tolerance study towards microbicide use. Sexual Health 5:3, 273
CrossRef102
Beth A. Auslander, Michelle M. Perfect, Daniel M. Breitkopf, Paul A. Succop, Susan L. Rosenthal. (2007) Microbicides: Information, Beliefs, and Preferences for Insertion. Journal of Women's Health 16:10, 1458-1467
CrossRef103
Andrzej Kulczycki. (2007) Ethics, Ideology, and Reproductive Health Policy in the United States. Studies in Family Planning 38:4, 333-351
CrossRef104
Jeffrey F. Peipert, Kate L. Lapane, Jenifer E. Allsworth, Colleen A. Redding, Jeffrey L. Blume, Faye Lozowski, Michael D. Stein. (2007) Women at risk for sexually transmitted diseases: correlates of intercourse without barrier contraception. American Journal of Obstetrics and Gynecology 197:5, 474.e1-474.e8
CrossRef105
A. Potthoff, N.H. Brockmeyer, . (2007) Immundefizienz und Krebs. Der Onkologe 13:11, 993-999
CrossRef106
Peter Sasieni. (2007) Cervical cancer prevention and hormonal contraception. The Lancet 370:9599, 1591-1592
CrossRef107
M. Stanley. (2007) Prevention strategies against the human papillomavirus: The effectiveness of vaccination. Gynecologic Oncology 107:2, S19-S23
CrossRef108
Scott D. Rhodes, Kenneth C. Hergenrather, Leland J. Yee, Aimee M. Wilkin, Thomas L. Clarke, Rich Wooldredge, Monica Brown, A. Bernard Davis. (2007) Condom Acquisition and Preferences within a Sample of Sexually Active Gay and Bisexual Men in the Southern United States. AIDS Patient Care and STDs 21:11, 861-870
CrossRef109
Mary B. Short, Paul A. Succop, Ana M. Ugueto, Susan L. Rosenthal. (2007) Predictors of Using a Microbicide-Like Product among Adolescent Girls. Journal of Adolescent Health 41:4, 357-362
CrossRef110
Sunny Kim, Mario De La Rosa, Mary Jo Trepka, and Megan Kelley. (2007) Condom Use Among Unmarried Students in a Hispanic-Serving University. AIDS Education and Prevention 19:5, 448-461
CrossRef111
Mark Schiffman, Philip E Castle, Jose Jeronimo, Ana C Rodriguez, Sholom Wacholder. (2007) Human papillomavirus and cervical cancer. The Lancet 370:9590, 890-907
CrossRef112
Alex Ferenczy, Eduardo L Franco. (2007) Prophylactic human papillomavirus vaccines: potential for sea change. Expert Review of Vaccines 6:4, 511-525
CrossRef113
Hein J. Boot, Iris Wallenburg, Hester E. de Melker, Marie-José M. Mangen, Annette A.M. Gerritsen, Nicoline A. van der Maas, Johannes Berkhof, Chris J.L.M. Meijer, Tjeerd G. Kimman. (2007) Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 25:33, 6245-6256
CrossRef114
Anthony Luke, Pierre d'Hemecourt. (2007) Prevention of Infectious Diseases in Athletes. Clinics in Sports Medicine 26:3, 321-344
CrossRef115
Anita L Nelson. (2007) Reversible female contraception: current options and new developments. Expert Review of Medical Devices 4:2, 241-252
CrossRef116
Graham A. Colditz. (2007) From epidemiology to cancer prevention: implications for the 21st Century. Cancer Causes & Control 18:2, 117-123
CrossRef117
J R Nichols, S H Stovall, R F Jacobs. (2007) Human Papillomavirus Infection: The Role of Vaccination in Pediatric Patients. Clinical Pharmacology & Therapeutics
CrossRef118
Norman A. Constantine, Petra Jerman. (2007) Acceptance of Human Papillomavirus Vaccination among Californian Parents of Daughters: A Representative Statewide Analysis. Journal of Adolescent Health 40:2, 108-115
CrossRef119
Joseph K. B. Matovu, Ronald H. Gray, Noah Kiwanuka, Godfrey Kigozi, Fred Wabwire-Mangen, Fred Nalugoda, David Serwadda, Nelson K. Sewankambo, Maria J. Wawer. (2007) Repeat Voluntary HIV Counseling and Testing (VCT), Sexual Risk Behavior and HIV Incidence in Rakai, Uganda. AIDS and Behavior 11:1, 71-78
CrossRef120
PD Griffiths. (2007) Anticipating full benefits from the new papillomavirus vaccines. Reviews in Medical Virology 17:1, 1-3
CrossRef121
B.H. Thiers. (2007) Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women. Yearbook of Dermatology and Dermatologic Surgery 2007, 139-140
CrossRef122
J. Bringman. (2007) Condom Use and Risk of Genital Human Papillomavirus Infection in Young Women. Yearbook of Obstetrics, Gynecology and Women's Health 2007, 264-265
CrossRef123
-S. London. (2006) Frequent Male Condom Use Decreases Women's Risk of HPV Infection. Perspectives on Sexual and Reproductive Health 38:4, 228-229
CrossRef124
Nicola Low, Nathalie Broutet, Yaw Adu-Sarkodie, Pelham Barton, Mazeda Hossain, Sarah Hawkes. (2006) Global control of sexually transmitted infections. The Lancet 368:9551, 2001-2016
CrossRef125
F. Martinón-Torres, E. Bernaola Iturbe, F. Giménez Sánchez, M. Baca Cots, F. de Juan Martín, J. Díez Domingo, M. Garcés Sánchez, J.A. Gómez Campderá, J.J. Picazo, V. Pineda Solas. (2006) Vacuna frente al virus del papiloma humano: un nuevo reto para el pediatra. Anales de Pediatría 65:5, 461-469
CrossRef126
Fengyi Jin, Garrett P. Prestage, Susan C. Kippax, Catherine M. Pell, Basil Donovan, David J. Templeton, John M. Kaldor, Andrew E. Grulich. (2006) Risk Factors for Genital and Anal Warts in a Prospective Cohort of HIV-Negative Homosexual Men: The HIM Study. Sexually Transmitted Diseases PAP,
CrossRef127
Richard Roden, T.-C. Wu. (2006) How will HPV vaccines affect cervical cancer?. Nature Reviews Cancer 6:10, 753-763
CrossRef128
Evan R. Myers. (2006) HPV vaccines: now that they're here, how do we maximize their benefit?. Contraception 74:4, 277-279
CrossRef129
(2006) Condom Use and the Risk of HPV Infection. New England Journal of Medicine 355:13, 1388-1389
Full Text130
Ann N. Burchell, Rachel L. Winer, Silvia de Sanjosé, Eduardo L. Franco. (2006) Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24, S52-S61
CrossRef131
Steiner, Markus J., Cates, Willard Jr., . (2006) Condoms and Sexually-Transmitted Infections. New England Journal of Medicine 354:25, 2642-2643
Full Text132
S. Rachel Skinner, Melissa Kang. (2006) Human papillomavirus prevalence in Canberra high school students: significance for vaccination strategies and adolescent health. Sexual Health 3:4, 299
CrossRef
- Letters
